Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prognostic relevance of HRDness gene expression signature in ovarian high-grade serous carcinoma; JGOG3025-TR2 study.

British journal of cancer - 1 Apr 2023

Takamatsu Shiro, Yoshihara Kosuke, Baba Tsukasa, Shimada Muneaki, Yoshida Hiroshi, Kajiyama Hiroaki, Oda Katsutoshi, Mandai Masaki, Okamoto Aikou, Enomoto Takayuki, Matsumura Noriomi

Abstract excerpt

BACKGROUND: This study aimed to evaluate the homologous recombination repair pathway deficiency (HRD) in ovarian high-grade serous carcinoma (HGSC). METHODS: In the ovarian cancer data from The Cancer Genome Atlas, we identified genes differentially expressed between tumours with and without HRD genomic scars and named these genes "HRDness signature". We performed SNP array, RNA sequencing, and methylation array...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA2 Protein
Share to Carcinoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cystadenocarcinoma, Serous

Share to Mutation

Share to Neoplasm Recurrence, Local

Share to Ovarian Neoplasms

Share to Prognosis

Share to Transcriptome

Source

Open in PubMed Open full text

Identifiers

PMID: 36593360
DOI: 10.1038/s41416-022-02122-9
PMCID: PMC10006095

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prognostic relevance of HRDness gene expression signature in ovarian high-grade serous carcinoma; JGOG3025-TR2 study.PMID 36593360Read ↗

Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma.Semantic proximity Read ↗

Homologous recombination deficiency in high-grade serous ovarian carcinoma: clinical pathological characteristics, impact of neoadjuvant chemotherapy, and prognostic implications.Semantic proximity Read ↗

IdentifiHR: predicting homologous recombination deficiency in high-grade serous ovarian carcinoma using gene expressionSemantic proximity Read ↗

Real-World Analysis of HRD Assay Variability in High-Grade Serous Ovarian Cancer: Impacts of BRCA1/2 Mutation Subtypes on HRD Assessment.Semantic proximity Read ↗

Molecular Subgroups of HRD Positive Ovarian Cancer and Their Prognostic Significance.Semantic proximity Read ↗

The Scarface Score: Deciphering Response to DNA Damage Agents in High-Grade Serous Ovarian Cancer—A GEICO StudySemantic proximity Read ↗

Mutational Signature-Based Biomarker for Phase II Trial of Olaparib Maintenance in Advanced High-Grade Ovarian Cancer.Semantic proximity Read ↗

Molecular classification of ovarian high-grade serous/endometrioid carcinomas through multi-omics analysis: JGOG3025-TR2 study.Semantic proximity Read ↗

Classification of High-Grade Serous Ovarian Carcinoma by Epithelial-to-Mesenchymal Transition Signature and Homologous Recombination Repair Genes.Semantic proximity Read ↗

Clinical characteristics of ovarian cancer classified by BRCA1, BRCA2, and RAD51C status.Semantic proximity Read ↗

Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancerSemantic proximity Read ↗

Beyond <i>BRCA</i> deficiency: Clinical and molecular predictors of survival in patients with <i>BRCA</i>-deficient tubo-ovarian high-grade serous carcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.